Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell Lung cancer

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9371-9380

  Gao, Yuanyuan ^a   Wang, Yan ^a   Sun, Lichun ^a   Meng, Qingwei ^a   Cai, Li ^a   Dong, Xiaoqun ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

EHD1; Non small cell lung cancer (NSCLC); Survival; TGF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; EPS15 HOMOLOGY DOMAIN 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; EHD1 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENDOCYTOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSFORMING GROWTH FACTOR BETA1; VESICULAR TRANSPORT PROTEINS;

EID: 84919868334     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2164-x     Document Type: Article

References (32)

1. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer J Int du Cancer. 2013;132(5):1162–9. doi:10.1002/ijc.27719.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
3. Walker J, Sawhney A, Hansen CH, Symeonides S, Martin P, Murray G, et al. Treatment of depression in people with lung cancer: a systematic review. Lung Cancer. 2013;79(1):46–53. doi:10.1016/j.lungcan.2012.09.014.
4. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. American College of Chest P. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):234S–42S. doi:10.1378/chest.07-1378.
5. Anderson CS, Curran WJ. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol. 2010;20(3):186–91. doi:10.1016/j.semradonc.2010.01.007.
6. Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20(3):204–9. doi:10.1053/j.semtcvs.2008.09.007.
7. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992;52(24):6949–52.
8. Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D. Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia. Growth Factors (Chur, Switzerland). 1990;2(2-3):149–55.
9. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103(2):295–309.
10. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol: Off Publication Int Assoc Study Lung Cancer. 2010;5(4):417–9. doi:10.1097/JTO.0b013e3181ce3afd.
11. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Holtta E. TGF-beta signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol. 2012;181(6):2202–16. doi:10.1016/j.ajpath.2012.08.027.
12. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, et al. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med. 2008;177(8):896–905. doi:10.1164/rccm.200707-1083OC.
13. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807–21. doi:10.1038/nrc1208.
14. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197–228. doi:10.1016/j.bbadis.2008.01.006.
15. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100(15):8621–3. doi:10.1073/pnas.1633291100.
16. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993;105(6):1846–56.
17. Booth C, Harnden P, Selby PJ, Southgate J. Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol. 2002;198(3):359–68. doi:10.1002/path.1214.
18. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, et al. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res. 1990;10(5A):1115–26.
19. Inoue T, Ishida T, Takenoyama M, Sugio K, Sugimachi K. The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. Surg Oncol. 1995;4(1):51–7.
20. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91(5):964–71.
21. Takanami I, Tanaka F, Hashizume T, Kodaira S. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol. 1997;64(4):262–7.
22. Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends Cell Biol. 2011;21(2):122–31. doi:10.1016/j.tcb.2010.10.003.
23. Sato M, Sato K, Liou W, Pant S, Harada A, Grant BD. Regulation of endocytic recycling by C. elegans Rab35 and its regulator RME-4, a coated-pit protein. EMBO J. 2008;27(8):1183–96.
24. Caplan S, Naslavsky N, Hartnell LM, Lodge R, Polishchuk RS, Donaldson JG, et al. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J. 2002;21(11):2557–67. doi:10.1093/emboj/21.11.2557.
25. Chen YG. Endocytic regulation of TGF-beta signaling. Cell Res. 2009;19(1):58–70. doi:10.1038/cr.2008.315.
26. Bennett WP, El-Deiry WS, Rush WL, Guinee Jr DG, Freedman AN, Caporaso NE, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 1998;4(6):1499–506.
27. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223(2):205–18. doi:10.1002/path.2785.
28. Lu H, Meng Q, Wen Y, Hu J, Zhao Y, Cai L. Increased EHD1 in non-small cell lung cancer predicts poor survival. Thoracic Cancer. 2013;4(4):422–32.
29. Jansen FH, Krijgsveld J, van Rijswijk A, van den Bemd GJ, van den Berg MS, van Weerden WM, et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Molecular Cellular Proteomics: MCP. 2009;8(6):1192–205. doi:10.1074/mcp.M800443-MCP200.
30. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007;110(8):3015–27. doi:10.1182/blood-2006-12-061507.
31. Wu Z-Z, Lu H-P, Chao CC-K. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol. 2010;80(2):262–76.
32. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009;119(6):1571–82. doi:10.1172/JCI37480.